- Pacific Biosciences (PACB +11.6%) receives an upgrade to Overweight from Neutral by JPMorgan analyst Tycho Peterson.
- He expects share price to triple to $15, up from his previous target of $5.
- Recent talk with the company's new CEO Christian Henry, left him 'encouraged about the abundant opportunities that lie ahead.'
- He further adds, given Henry's 'impressive track record' along with what he sees as low hanging fruit on the commercial front, Peterson said he feels confident about the new management team's ability to execute on its new strategy.
- A look at the financials and escalating revenue numbers here.
Friday, October 2, 2020
Pacific Biosciences up as JP Morgan analyst triples price target
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.